Vaccinology: Next-Generation Advances in Transforming Immunity
May 16–19, 2027 | Fairmont Hotel Vancouver, Vancouver, BC, Canada
Scientific Organizers:
Saranya Sridhar, Debora Marks, and Teresa Lambe
×
-
May 16–19, 2027 | Fairmont Hotel Vancouver, Vancouver, BC, Canada
Scientific Organizers: Saranya Sridhar, Debora Marks, and Teresa Lambe
Saranya Sridhar
Sanofi
Saranya Sridhar, M.B.B.S., M.S., D.Phil., DFPH, is Head of Global Clinical Development for Vaccines at Sanofi, where he leads end-to-end clinical research from translational medicine through life cycle management. With over 20 years in vaccine R&D, he has led the clinical development and regulatory approval of Sanofi's COVID-19 vaccine, contributed to the first dengue vaccine approval, and advanced next-generation respiratory vaccines. He identified the first T-cell correlate of protection against pandemic influenza in humans and has extensive experience in regulatory interactions with FDA, EMA, and WHO. He is a Rhodes Scholar and completed his D.Phil. at Oxford University, where he developed adenoviral vectored vaccines for malaria and tuberculosis.
Debora Marks, PhD
Harvard Medical School
Debora Marks, Ph.D., is a Professor at Harvard Medical School and a world-leading computational biologist whose work has fundamentally shaped how artificial intelligence is applied to biology. Her lab develops machine learning methods grounded in evolutionary principles, with a distinctive emphasis on interpretability and causality, and her research established that three-dimensional protein structures can be predicted from sequence alone, a foundational advance that informed subsequent breakthroughs in the field. Her group has since revealed the fitness effects of human genetic variation at scale, built foundational generative models for proteins, antibodies, and genomes, and pioneered computational approaches to pandemic preparedness and vaccine development. She has received numerous awards for her contributions to computational biology, including election to the Fellowship of the Royal Society and the Margot and Tom Pritzker Prize for AI in Science Research Excellence, both in 2026. Her work bridges fundamental science and translational impact across medicine, biosecurity, and sustainability.
Teresa Lambe, PhD
University of Oxford
Teresa Lambe, Ph.D., is the Calleva Head of Vaccine Immunology and a Professor of Vaccinology and Immunology at the University of Oxford, where she leads a research group focused on improving human health by controlling disease through vaccination. She is one of the Principal Investigators overseeing the Oxford/AstraZeneca vaccine programme, having co-designed the vaccine in January 2020, led the preclinical studies, and overseen the delivery of immune results needed to support regulatory approval in late 2020, with the vaccine estimated to have saved more than 6 million lives globally. Her group is currently developing and testing vaccines against a number of outbreak pathogens, including Crimean-Congo haemorrhagic fever virus, Ebola virus, Marburg virus, and coronaviruses, several of which have progressed to clinical trials. She was appointed an honorary OBE for her services to science and public health in the 2021 Queen's Birthday Honours and received the Presidential Distinguished Service Award for the Irish Abroad in 2022.
Available Formats:
Supported by:
Livestream
In Person
On Demand
***Meeting program subject to change.
Available Formats: = Livestream = In Person = On DemandMerchandise Options
Registration Options
Sunday, May 16, 2027
Fundraising
Registration
4:00–8:00 PM
British/Columbia Foyer
Welcome Mixer
6:00–8:00 PM
British/Columbia Foyer
Monday, May 17, 2027
Breakfast
7:30–8:30 AM
Pacific Ballroom, Vancouver Island Room
Welcome Remarks (Joint)
8:30–8:40 AM
British/Columbia Ballroom
Keynote Address (Joint)
8:40–9:30 AM
British/Columbia Ballroom
Michel C. Nussenzweig, HHMI/Rockefeller University
Immune Strategies to Combat Infectious Diseases: What Works and What Doesn't
Immune Strategies to Combat Infectious Diseases: What Works and What Doesn't
Transformative Technologies for Infectious Disease Therapeutics and Vaccines (Joint)
9:30–12:00 PM
British/Columbia Ballroom
Debora Marks, Harvard Medical School
Beating Viruses at their Own Game
Beating Viruses at their Own Game
Kevin Wiehe, Duke University
Mutation Guided Immunogen Design
Mutation Guided Immunogen Design
Pamela J Bjorkman, California Institute of Technology
Structure based Vaccine Design
Structure based Vaccine Design
Darrell J. Irvine, Scripps Research Institute
Harnessing Novel Vaccine Dosing and Adjuvant Strategies
Harnessing Novel Vaccine Dosing and Adjuvant Strategies
Coffee Break
10:00–10:20 AM
British/Columbia Foyer
Panel Discussion 1: Vaccine Hesitancy and Distrust (Joint)
12:10–1:10 PM
British/Columbia Ballroom
Poster Setup
12:30–1:00 PM
Pacific Ballroom, Vancouver Island Room
On Own for Lunch
1:10–2:30 PM
Poster Viewing
1:10–10:00 PM
Pacific Ballroom, Vancouver Island Room
Symposia Spotlight 1
2:30–4:30 PM
British Ballroom
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
British/Columbia Foyer
Designing Precision Vaccines
5:00–7:00 PM
British Ballroom
Bali Pulendran, Stanford University School of Medicine
Next Generation Immunology to Design Precision Vaccines
Next Generation Immunology to Design Precision Vaccines
Galit Alter, AstraZeneca
Systems Immunology for Precision Vaccinology
Systems Immunology for Precision Vaccinology
Katherine Kedzierska, University of Melbourne
Immune System Evolution through the Lifespan: Designing Precision Vaccines
Immune System Evolution through the Lifespan: Designing Precision Vaccines
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Pacific Ballroom, Vancouver Island Room
Poster Session 1
7:30–10:00 PM
Pacific Ballroom, Vancouver Island Room
Tuesday, May 18, 2027
Breakfast
7:30–8:30 AM
Pacific Ballroom, Vancouver Island Room
Tissue Targeting Vaccines
8:30–11:30 AM
British Ballroom
Laura K. Mackay, University of Melbourne
Protection against Respiratory Pathogens: Role of Tissue-Resident Immunity
Protection against Respiratory Pathogens: Role of Tissue-Resident Immunity
Mala K. Maini, University College London
Protection against Hepatitis B: Compartmentalized Tissue-Specific Immunity
Protection against Hepatitis B: Compartmentalized Tissue-Specific Immunity
Ali H Ellebedy, Washington University School of Medicine
How Germinal Center Dynamics Shape Antibody Responses to Vaccination
How Germinal Center Dynamics Shape Antibody Responses to Vaccination
Barbara L. Shacklett, University of California, Davis
Genital Mucosal Immunity: T-cell Immunity to HIV
Genital Mucosal Immunity: T-cell Immunity to HIV
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
British/Columbia Foyer
Panel Discussion 2: Advances in Regulatory Framework for Combination Vaccines
11:40–12:40 PM
British Ballroom
Poster Setup
12:40–1:00 PM
Pacific Ballroom, Vancouver Island Room
On Own for Lunch
12:40–2:30 PM
Poster Viewing
1:00–10:00 PM
Pacific Ballroom, Vancouver Island Room
Career Roundtable (Joint)
2:30–3:30 PM
Columbia Ballroom
Panel 3: Global Virus Network (Joint)
3:30–4:30 PM
Columbia Ballroom
Coffee Available
4:30–5:00 PM
British/Columbia Foyer
Vaccines for Global Health
5:00–7:00 PM
British Ballroom
Simon J. Draper, University of Oxford
New Malaria Vaccines: A Changing World
New Malaria Vaccines: A Changing World
Thomas J Scriba, University of Cape Town
A New TB Vaccine: Results of the M72/AS01B Phase 3 Trial
A New TB Vaccine: Results of the M72/AS01B Phase 3 Trial
Teresa Lambe, University of Oxford
Vaccines for Global Health
Vaccines for Global Health
Short Talk(s) Chosen from Abstracts
Social Hour with Dinner
7:00–8:00 PM
Pacific Ballroom, Vancouver Island Room
Poster Session 2
7:30–10:00 PM
Pacific Ballroom, Vancouver Island Room
Wednesday, May 19, 2027
Breakfast
7:30–8:30 AM
Pacific Ballroom, Vancouver Island Room
New Frontiers of Vaccines: Cancer, Allergy and Beyond
8:30–11:30 AM
British Ballroom
Speaker to be Announced
Jeffrey A Hubbell, New York University
Synthetic Antigen Design for Targeting: From Cancer to Tolerogenic Vaccines
Synthetic Antigen Design for Targeting: From Cancer to Tolerogenic Vaccines
Saranya Sridhar, Sanofi
Therapeutic Vaccines against Inflammatory Diseases
Therapeutic Vaccines against Inflammatory Diseases
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
British/Columbia Foyer
Panel Discussion 4: Academic-Industry Collaborations: Ways to Make it Work
11:40–12:40 PM
British Ballroom
On Own for Lunch
12:40–2:30 PM
Symposia Spotlight 2
2:30–4:30 PM
British Ballroom
Short Talks Chosen from Abstracts
Coffee Available
4:30–5:00 PM
British/Columbia Foyer
What are the Next Generation Methodologies to Revolutionize Vaccine Development?
5:00–6:45 PM
British Ballroom
Tor Biering-Sørensen, University of Copenhagen
Real-World Individual Randomized Clinical Trials: FLUNITY
Real-World Individual Randomized Clinical Trials: FLUNITY
Speaker to be Announced
Kawsar R. Talaat, Johns Hopkins Bloomberg School of Public Health
CHIM Studies: A New Pathway to License Vaccines
CHIM Studies: A New Pathway to License Vaccines
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions
6:45–7:00 PM
British Ballroom
Social Hour with Dinner
7:00–8:00 PM
Pacific Ballroom, Vancouver Island Room
Entertainment
8:00–11:00 PM
Thursday, May 20, 2027
Departure
12:00–11:59 PM
Subscribe for Updates